Pulmonary arterial hypertension: future directions: report of a National Heart, Lung and Blood Institute/Office of Rare Diseases workshop

Circulation. 2004 Jun 22;109(24):2947-52. doi: 10.1161/01.CIR.0000132476.87231.6F.
No abstract available

Publication types

  • Congress
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Animals
  • Arginine / therapeutic use
  • Bone Morphogenetic Protein Receptors, Type II
  • Enzyme Inhibitors / pharmacology
  • Enzyme Inhibitors / therapeutic use
  • Female
  • Forecasting
  • Genetic Predisposition to Disease
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
  • Hypertension, Pulmonary* / complications
  • Hypertension, Pulmonary* / genetics
  • Hypertension, Pulmonary* / mortality
  • Hypertension, Pulmonary* / therapy
  • Male
  • Models, Biological
  • Pancreatic Elastase / antagonists & inhibitors
  • Platelet Aggregation Inhibitors / therapeutic use
  • Potassium Channels / physiology
  • Protein Serine-Threonine Kinases / genetics
  • Rats
  • Research / trends
  • Signal Transduction

Substances

  • Enzyme Inhibitors
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Platelet Aggregation Inhibitors
  • Potassium Channels
  • Arginine
  • Protein Serine-Threonine Kinases
  • BMPR2 protein, human
  • Bmpr2 protein, rat
  • Bone Morphogenetic Protein Receptors, Type II
  • Pancreatic Elastase